Haydar Soydaner Karakuş

Haydar Soydaner Karakuş

Auto-generated profile, based on publicly available information

Haydar Soydaner Karakuş

Department of Pulmonary Diseases, Faculty of Medicine Ege University Izmir Türkiye

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2015 in Mikrobiyoloji Bulteni
Verified
Journal Article
Closed access
CÇCandan Çi̇çEk
Candan Çi̇çEk
AAAyşe ARSLAN
Ayşe ARSLAN
HKHaydar Soydaner Karakuş
Haydar Soydaner Karakuş
MYMehmet Yalaz
Mehmet Yalaz
ESEylem Ulaş SAZ
Eylem Ulaş SAZ
GÇGürsel Çok
Gürsel Çok
<%=header_description %> <%=header_description %>

1 April 2002 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
ADAysegul Dirlik
Aysegul Dirlik
ZBZeynep Burak
Zeynep Burak
TGTuneay Goksel
Tuneay Goksel
RERuya Erine
Ruya Erine
HKHaydar Karakus
Haydar Karakus
MOMustafa Ozhan
Mustafa Ozhan

25 July 2014 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ÖGÖzlem Göksel
Özlem Göksel
TGTuncay Goksel
Tuncay Goksel
GCGursel Cok
Gursel Cok
HKHaydar Karakus
Haydar Karakus
FBFeza Bacakoglu
Feza Bacakoglu
MEMunevver Erdinc
Munevver Erdinc

18 September 2025 in Thoracic Research and Practice
Verified
Journal Article
Open access
PDF file
YKYusuf Kahya
Yusuf Kahya
FMFeride Marım
Feride Marım
GSGokcen Omeroglu Simsek
Gokcen Omeroglu Simsek
HKHaydar Soydaner Karakuş
Haydar Soydaner Karakuş
SÖSevin Başer Öncel
Sevin Başer Öncel
TGTuncay Göksel
Tuncay Göksel
Update: The New 9th Edition TNM Classification for Lung Cancer Is Now in Use - Thoracic Research and Practice

23 April 2022 in Adıyaman Üniversitesi Sağlık Bilimleri Dergisi
Verified
Journal Article
Open access
PDF file
ÖUÖzlem Uğur
Özlem Uğur
HMHatice Mert
Hatice Mert
EKEzgi Karadağ
Ezgi Karadağ
HKHaydar Soydaner Karakuş
Haydar Soydaner Karakuş
TYTugba Yavuzsen
Tugba Yavuzsen
CBCanan Demi̇r Barutcu
Canan Demi̇r Barutcu
Aim: The aim was to identify symptoms experienced by patients with lung cancer who had received chemotherapy and to determine the symptom clusters.Materials and Methods: This was a descriptive and cross-sectional study. A Patient Presentation Form, the ECOG Performance Scale, and the Memorial Symptom Assessment Scale were used. The data were collected between September 2016 and June 2017. The sample of the study consisted of 100 patients who met the selection criteria.Results: When the prevalence of the symptoms experienced by the patients was examined, the most common complaints were lack of energy (82%), loss of appetite (71%), change in taste of food (62%), anxiety and feeling irritable (69%). The most common symptoms were weakness (8%), loss of appetite (14%), anxiety (20%) and feeling sad (28%).Conclusion: When the occurrence and severity ratings were examined, the symptoms could be placed into five groups: the gastrointestinal system cluster, the psychology cluster, the respiratory cluster, the neurology cluster, and the cluster of skin changes. The symptoms of lung cancer patients interact with each other and should be managed with appropriate interventions. Moreover, health professionals’ awareness of symptom management should be improved.

3 June 2026 in Cancer Reports
Verified
Journal Article
Open access
SLSabina Latifova
Sabina Latifova
UGUygar Genis
Uygar Genis
HKHaydar Soydaner Karakus
Haydar Soydaner Karakus
KKKorcan Korba
Korcan Korba
SÖSu ÖZGÜR
Su ÖZGÜR
AVAslı Tetik Vardarlı
Aslı Tetik Vardarlı
Background: Advanced non‐small cell lung cancer (NSCLC), particularly lung adenocarcinoma, remains a leading cause of cancer‐related mortality. Although molecular profiling has improved disease stratification, most biomarker assays rely on invasive tissue sampling. Exhaled breath condensate (EBC) is an attractive non‐invasive biofluid that may provide clinically relevant molecular information. This study evaluated whether cell‐free RNA (cfRNA) obtained from EBC can capture diagnostically and prognostically informative gene‐expression changes in advanced lung adenocarcinoma. Methods: In this prospective study, 40 patients with histologically confirmed stage IIIB–IV lung adenocarcinoma and 20 healthy controls were enrolled. EBC samples were collected from all participants, and plasma samples were obtained from a subgroup of 10 patients and 10 controls. Expression of EGFR, FGFR2, PIK3CA, PTEN, SMAD4, STK11, and TP53 was quantified by RT‐qPCR and normalized to GAPDH using the 2 −ΔΔCT method. Receiver operating characteristic (ROC) analysis, correlation testing, and Kaplan–Meier survival analysis were performed. Results: The most clinically relevant findings were observed for PIK3CA , FGFR2 , and EGFR . In EBC, PIK3CA emerged as the only gene with significant diagnostic performance for distinguishing patients from healthy controls (AUC = 0.8522; sensitivity 81.58%; specificity 76.92%). In survival analyses, high FGFR2 and high PIK3CA expression were associated with significantly shorter overall survival, supporting their prognostic relevance. In treatment‐stratified analysis, low EGFR expression was associated with longer survival in patients receiving chemotherapy alone, suggesting potential predictive value in this subgroup. In plasma, PIK3CA was upregulated approximately five‐fold, whereas EGFR was downregulated approximately five‐fold. Notably, EGFR expression showed a strong positive correlation between EBC and plasma ( R 2 = 0.7849, p = 0.0006), indicating cross‐matrix consistency for this marker. By contrast, alterations in PTEN , TP53 , and SMAD4 should be considered exploratory, as they showed differential expression but lacked comparable diagnostic, prognostic, or treatment‐associated strength. Conclusions: EBC‐based cfRNA profiling provides a feasible, non‐invasive approach for molecular characterization of advanced lung adenocarcinoma. Among the genes examined, PIK3CA showed the strongest diagnostic signal, FGFR2 demonstrated prognostic significance, and EGFR showed the clearest cross‐sample concordance and treatment‐associated relevance. Larger independent validation studies are required before clinical implementation.